<DOC>
	<DOCNO>NCT00001444</DOCNO>
	<brief_summary>This dosage escalation study estimate maximum tolerate dose staurosporine analogue UCN-01 . Groups 3 6 patient receive 72-hours intravenous continuous infusion UCN-01 day 1 day 4 cycle first cycle , 36-hours subsequent cycle . The side effect allow disappear 28 day . This cycle repeat evaluation follow-up , every 4 week , long patient benefit .</brief_summary>
	<brief_title>A Phase I Trial Continuous Infusion UCN-01 Patients With Refractory Neoplasms</brief_title>
	<detailed_description>Patients relapse refractory neoplasms treat escalate dos UCN-01 ( 7-hydroxystaurosporine ) protein kinase C inhibitor also may affect cyclin-dependent kinase activity , give 72 hour infusion . This trial determine toxicity associate maximally tolerate dose drug patient therapeutic approach deem useful .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients must histologic diagnosis solid tumor lymphoma confirm Laboratory Pathology , NCI fail standard chemotherapy . No patient leukemia , brain metastasis , primary brain tumor . Patients must older 18 year age . Must SGPT SGOT less 2.5 time upper normal limit . Liver tumor replacement le 50 % total liver surface . Total bilirubin must less 1.5 time upper limit measure creatinine clearance least 55 ml/min . Hemoglobin must great 9.0 . Platelet count must great 100,000 , absolute granulocyte count great 1,500 . PT/PTT must within normal range . Must performance status ECOG 02 . Must ability give inform consent . Must reliability return follow treatment , follow instruction . The patient must receive radiation therapy chemotherapy within past 4 week recover toxicity prior start therapy . Patients must receive nitrosureas , mitomycin C , bone seek radioisotope within 6 week entry . Patients prostate cancer : Must tumor progression follow blockade testicular adrenal androgen . If take flutamide antiandrogen , discontinue least four week prior treatment evidence progression disease follow maneuver . Leuprolide GnRh analog maintain patient orchiectomy . All prostate cancer patient must serum testosterone castrate range . Exposure suramin : Patients prior exposure suramin least 3 month therapy ( last day infusion ) undetectable suramin level . Patients breast carcinoma take hormonal treatment discontinue medication least 4 week prior treatment UCN01 show progression disease maneuver . Patients may treat follow present : Active infection , require antibiotic within 7 day prior entry . Bacterial colonization secondary percutaneous nephrostomy tube , ileal pouch , indwell urinary catheter . Positive serology HIV . Greater grade I peripheral neuropathy study entry . Prior radiation therapy great equal 30 % bone marrow . No patient local complication require urgent local therapy ( e.g . : untreated hydronephrosis , impend spinal cord compression , severe bone pain unresponsive analgesic ) . No patient history unstable newly diagnose angina pectoris , recent myocardial infarction ( within 6 month enrollment ) , class IIIV congestive heart failure , severe chronic obstructive lung disease ( forced vital capacity less 1000 ml ) . No patient uncontrolled seizure activity , control seizure activity less one year free seizure . Patients past history seizure must seizure free great year take anticonvulsant medication . No patient coagulopathy active renal disease . No patient receive steroid physiologic replacement . Effective June 10 , 1998 , patient history diabetes mellitus within 6 month enrollment fast glucose great equal 116/mg/dl Hemoglobin A1C great 6.5 mg/dl eligible . If patient premenopausal female must negative pregnancy test ( bHCG ) counsel concern necessity effective contraception No lactating female . Both male female patient must practice effective contraception study four month follow conclusion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Natural Products</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Protein Kinase Antagonist</keyword>
</DOC>